KING OF PRUSSIA, Pa.--(BUSINESS WIRE)--Genomind, a leader in medication management and personalized medicine through pharmacogenetics (PGx), is proud to announce the release of its innovative Patient ...
Expanded testing panel provides a better understanding of a patient’s genetic medication risk profile. Genomind’s real-time, interactive, medication management tool GenMedPro™ has expanded to include ...
Phase I data of oral amycretin, a co-agonist of GLP-1 and amylin receptors from Novo Nordisk A/S, showed a 13.1% reduction in body weight at 12 weeks vs. 1.1% for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results